Has The US Government Done Stem Cell Research?

In a recent posting on the blog CaNORML was an article on how the US Government has a patent on medical marijuana.

While researching that, we came across this patent that reads like stem cell research by the US Government is involved.

Post what you think please.

US Patent 7378277 - Methods and compositions for transforming dendritic cells and activating T cells

AssigneeThe United States of America as represented by the Department of Health and Human Services

US Patent Issued on May 27, 2008

Abstract

Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.

Inventor(s)
Hwu, Patrick
Reeves, Mark
Rosenberg, Steven A.

Assignee
The United States of America as represented by the Department of Health and Human Services
ApplicationNo. 10607327 filed on 06/26/2003
Current US Class435/455, Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE435/372, Blood, lymphatic, or bone marrow origin or derivative435/377, Method of altering the differentiation state of the cell424/93.21, Eukaryotic cell424/93.71Leukocyte
Field of Search435/455, Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/372, Blood, lymphatic, or bone marrow origin or derivative435/377, Method of altering the differentiation state of the cell424/93.21, Eukaryotic cell424/93.71Leukocyte
ExaminersPrimary: Wehbé, Anne Marie S.
Attorney, Agent or Firm
Townsend and Townsend and Crew LLP
Foreign Patent References
0563485 EP 10/01/1993
WO 93/18137 WO 09/01/1993
WO 94/16716 WO 08/01/1994
WO 94/27435 WO 12/01/1994
WO 95/06120 WO 03/01/1995
WO 95/34676 WO 12/01/1995
WO 97/03703 WO 02/01/1997
International classC12N 15/00;C12N 15/74;C12N 5/00;C12N 5/08

Other References
Chen et al., “Cytokine-mobilized peripheral blood CD34+THy-1+Lin-human hematopoietic stem cells as target cells for transplantation-based gene therapy”, Leukemia 9 Suppl 1:S17-S25 (1995).
Boehmelt et al., “Dendritic cell progenitor is transformed by a conditional v-Rel estrogen receptor fusion protein v-Re1ER”, Cell 80:2: 341-352 (1995).
Bakker et al., “Generation of antimelanoina cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro”, Cancer Res. 55:22: 5330-5334 (1995).
Siena et al., “Massive ex vivo generated of functional dendritic cells from CD34 blood progenitors for anticancer therapy”, Experimental Hematology 23:1463-1471 (1995).
Holland et al., “Differentiation of Human Hematopoietic Cells Increases Expression of a Gone Transferred by a Retroviral Vector”, Journal of Leukocyte Biology 46:221-229 (1989).
Alijagic et al., “Dendritic cells generated from peripheral blood transfected with human tyrpsomase induce specific T cell activation”, Eur. J. Immunol. 25:3100-3107 (1995).
Drexhage et al., “Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes”, Ci-204-Ci-207, 1994.
Rouse et al., “Induction in vitro of primary cytotoxic T-lymphocyte responses with DAN encoding herpes simplex virus proteins”, J. Virol., 68:9:5685-5689 (1994).
Reeves et al., “Retroviral transduction of human dendritic cells with a tumor-associated antigen gene”, Cancer Res 56:24:5672-5677 (1996).
Heemskerk et al., “Melanoma-specific CTL, generated in vitro using dendritic antigens”, (Meeting abstract), Gene Therapy of Cancer: 2nd European Conference, Sep. 7-8, 1995, London, A13, XP000675471.
Conry et al., “Selected strategies to augment polynucleotide immunization”, Gene Therapy 3:1: 67-74 (1996).
Miller et al. (1995) FASEB, vol. 9.
Deonarain et al. (1998) Exp. Opin. Ther. Patents, vol. 8 (1).
Chen et al. (1995) Proc. Natl. Acad. Sci., vol. 18(2), 8125-8129.
Alijagic et al. (1995) Eur. J. Immunol., vol. 25, 3100-3107.